Nektar Therapeutics (NKTR) Common Equity (2010 - 2026)

Nektar Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $576.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 4094.32% year-over-year to $576.2 million; the TTM figure through Mar 2026 stood at $576.2 million (up 4094.32% YoY), while the FY2025 annual figure was $89.8 million, up 47.9% from the prior year.
• Common Equity for Q1 2026 stood at $576.2 million, up from $89.8 million in the prior quarter.
• The five-year high for Common Equity was $607.9 million in Q1 2022, with the low at -$24.2 million in Q2 2025.
• The 5-year median for Common Equity is $131.0 million (2023), against an average of $213.5 million.
• The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 130.38% in 2025, then surged 4094.32% in 2026.
• Nektar Therapeutics' Common Equity stood at $366.6 million in 2022, then plunged by 64.27% to $131.0 million in 2023, then tumbled by 53.63% to $60.7 million in 2024, then soared by 47.9% to $89.8 million in 2025, then soared by 541.44% to $576.2 million in 2026.
• Business Quant data shows NKTR's Common Equity at $576.2 million in Q1 2026, $89.8 million in Q4 2025, and $85.1 million in Q3 2025.